
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Table of Contents
over 23 years ago
E-Learning FDA Styleover 23 years ago
Patient Data Come of Ageover 23 years ago
What's Really Driving Costs?over 23 years ago
Fourth Annual Pharm Exec 50over 23 years ago
The Riddle of Risk





